BURLINGAME, CA, Genesis Therapeutics, harnessing AI to create medicines for patients with severe diseases, announced a $200 million Oversubscribed Series B funding round.
Genesis Therapeutics, harnessing AI to create medicines for patients with severe diseases, announced a $200 million Oversubscribed Series B funding round led by Andreessen Horowitz, with participation from new investors, Fidelity Management & Research Company, BlackRock, and NVentures, with participation from existing investors, T. Rowe Price Associates, Rock Springs Capital, Radical Ventures, and Menlo Ventures.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our
about page.
